Moderna has asked the American FDA for emergency use authorization (Eua) for its mRna anti-Covid vaccine in adolescents aged 12 to 17. Today the product is approved in the population aged 18 and over. “We are pleased to announce that we have submitted to the FDA an application for emergency use authorization for our Covid-19 vaccine for use in adolescents in the United States – says Stéphane Bancel, CEO of the US company – We are encouraged by the fact that the Moderna vaccine has been highly effective in preventing Covid-19 and Sars-CoV-2 infection in adolescents. We have already requested approval from Health Canada and the European Drug Agency Ema – recalled the CEO – and we will apply to regulatory bodies around the world for this important younger age population. We remain committed to helping end the Covid-19 pandemic. ”
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.